BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its third quarter 2011 financial results on Thursday, November 3, 2011, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Thursday, November 3, 2011
1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET)
- Telephone 877-941-6010 (domestic) or 480-629-9772 (international); conference ID 4480558
- Webcast available at http://www.seattlegenetics.com in the Investors and News section
- Telephone replay will be available beginning at approximately 3:30 p.m. PT on Thursday, November 3, 2011, through 3:30 p.m. PT on Monday, November 7, 2011, by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4480558
- Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com in the Investors and News section
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. ADCETRIS™ (brentuximab vedotin) was approved by the U.S. Food and Drug Administration on August 19, 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
KEYWORDS: United States North America Washington
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical